FineMark National Bank & Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

FineMark National Bank & Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,725	Closed	-$206K	–	450
2021 Q1	$206K	Buy	2,725 +225	+9%	+$18.4K	0.01%	420
2020 Q4	$219K	Buy	+2,500	New	+$198K	0.01%	385
2017 Q1	–	Sell	-76	Closed	-$6K	–	442
2016 Q4	$6K	Hold	76	–	–	﹤0.01%	1030
2016 Q3	$7K	Hold	76	–	–	﹤0.01%	1006
2016 Q2	$6K	Hold	76	–	–	﹤0.01%	1035
2016 Q1	$6K	Hold	76	–	–	﹤0.01%	1003
2015 Q4	$8K	Buy	76 +14	+23%	+$1.46K	﹤0.01%	974
2015 Q3	$7K	Buy	+62	New	+$8.28K	﹤0.01%	1028
2013 Q4	–	Sell	-219	Closed	-$16K	–	1571
2013 Q3	$16K	Buy	+219	New	+$14.6K	﹤0.01%	867

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FineMark National Bank & Trust's BMRN Position: Q2 2021 in Review

FineMark National Bank & Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 2,725 shares — an estimated $206K sold.

FineMark National Bank & Trust first reported a position in BMRN in Q3 2013 and held it in 9 quarters. The position peaked at $219K in Q4 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

FineMark National Bank & Trust reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
FineMark National Bank & Trust sold 2,725 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $206K.
FineMark National Bank & Trust first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 9 quarters.
FineMark National Bank & Trust's BioMarin Pharmaceuticals position peaked at $219K in Q4 2020.
530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on FineMark National Bank & Trust's 13F filing for Q2 2021, filed 13 Aug 2021.